Summary
164.25 1.41(0.87%)03/18/2025
Johnson & Johnson (JNJ)
JNJ reported last earnings on 2025-01-22 after the market. An EPS of $2.04 was observed compared to an estimated EPS of $1.99, resulting in a surprise value of $0.05. A revenue of $22,520 million was observed compared to an estimated revenue of $22,431 million, resulting in a surprise value of $89 Million.
Johnson & Johnson (JNJ)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.87 | 0.86 | 5.97 | 14.38 | 0.45 | 8.14 | 48.75 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Buy |
| ROA | Strong Buy |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 164.25 | |
| Open | 163.44 | |
| High | 164.86 | |
| Low | 162.97 | |
| Volume | 7,341,843 | |
| Change | 1.41 | |
| Change % | 0.87 | |
| Avg Volume (20 Days) | 9,532,815 | |
| Volume/Avg Volume (20 Days) Ratio | 0.77 | |
| 52 Week Range | 139.88 - 169.99 | |
| Price vs 52 Week High | -3.38% | |
| Price vs 52 Week Low | 17.42% | |
| Range | 0.00 | |
| Gap Up/Down | -0.06 | |
Profitibility | ||
| Market Capitalization (Mln) | 392,057 | |
| Revenue per share | 36.9023 | |
| Net Income per share | 5.8440 | |
| Dividend Yield | 0.0302 | |
| Dividend Share | 496.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 28.1059 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
03/18 08:03 EST - prnewswire.com
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation SPRING HOUSE, Pa. , March 18, 2025...
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation SPRING HOUSE, Pa. , March 18, 2025...
03/18 04:34 EST - fool.com
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.
Some companies are just better than others at paying dividends. They offer higher-yielding payouts that they steadily increase in good times and bad.
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.
Some companies are just better than others at paying dividends. They offer higher-yielding payouts that they steadily increase in good times and bad.
03/17 08:46 EST - marketbeat.com
Resilient Investing: 3 Stocks Built to Weather Market Volatility
As inflationary pressures persist and the specter of a potential recession looms, investors are understandably seeking stability. While predicting market movements is always challenging, focusing on companies with inherent resilience offers a sound strategy for navigating uncertain economic waters.
Resilient Investing: 3 Stocks Built to Weather Market Volatility
As inflationary pressures persist and the specter of a potential recession looms, investors are understandably seeking stability. While predicting market movements is always challenging, focusing on companies with inherent resilience offers a sound strategy for navigating uncertain economic waters.
03/17 04:41 EST - fool.com
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now
It's official! As of the closing bell on March 13, the benchmark S&P 500 (^GSPC 2.13%), which is comprised of 500 of the most-influential businesses traded on U.S. stock exchanges, had entered correction territory.
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now
It's official! As of the closing bell on March 13, the benchmark S&P 500 (^GSPC 2.13%), which is comprised of 500 of the most-influential businesses traded on U.S. stock exchanges, had entered correction territory.
03/16 13:40 EST - seekingalpha.com
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high...
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high...
03/15 05:07 EST - businessinsider.com
An AI imaging firm says Johnson & Johnson stole its tech. Execs on both sides are expected to testify next week.
Johnson & Johnson executives are scheduled to take the stand in a trial starting Monday. ChemImage, a small biotech firm, sued the healthcare giant over a 2019 partnership that went south.
An AI imaging firm says Johnson & Johnson stole its tech. Execs on both sides are expected to testify next week.
Johnson & Johnson executives are scheduled to take the stand in a trial starting Monday. ChemImage, a small biotech firm, sued the healthcare giant over a 2019 partnership that went south.
03/14 12:45 EST - zacks.com
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
03/12 15:49 EST - 247wallst.com
Forget About a Market Correction: Baby Boomers Should Buy These 3 Bulletproof Dividend Stocks Now
Market volatility can be unsettling for any investor.
Forget About a Market Correction: Baby Boomers Should Buy These 3 Bulletproof Dividend Stocks Now
Market volatility can be unsettling for any investor.
03/12 12:58 EST - businesswire.com
Six Dean Omar Branham Shirley Attorneys Honored for Representation of Plaintiffs
DALLAS--(BUSINESS WIRE)--Leading plaintiff trial firm Dean Omar Branham Shirley, LLP is pleased to announce the selection of partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly and attorney Mark Linder to the list of Lawdragon's 500 Leading Plaintiff Consumer Lawyers for 2025....
Six Dean Omar Branham Shirley Attorneys Honored for Representation of Plaintiffs
DALLAS--(BUSINESS WIRE)--Leading plaintiff trial firm Dean Omar Branham Shirley, LLP is pleased to announce the selection of partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly and attorney Mark Linder to the list of Lawdragon's 500 Leading Plaintiff Consumer Lawyers for 2025....
03/12 12:16 EST - finbold.com
ChatGPT picks 3 safe haven stocks to buy for 2025
The advent of artificial intelligence (AI) and machine learning has, in many ways, revolutionized the financial markets.
ChatGPT picks 3 safe haven stocks to buy for 2025
The advent of artificial intelligence (AI) and machine learning has, in many ways, revolutionized the financial markets.
03/11 10:38 EST - youtube.com
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
03/10 13:20 EST - 247wallst.com
3 Dividend Stocks Set to Provide Stability in Market Chaos
Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.
3 Dividend Stocks Set to Provide Stability in Market Chaos
Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.
03/10 08:00 EST - prnewswire.com
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data...
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data...
03/08 09:00 EST - prnewswire.com
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase...
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase...
03/07 13:45 EST - zacks.com
JNJ Halts Development of Depression Drug Over Efficacy Concerns
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.
JNJ Halts Development of Depression Drug Over Efficacy Concerns
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.
03/07 12:15 EST - zacks.com
3 Dividend Kings Shaking Off Market Woes
While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.
3 Dividend Kings Shaking Off Market Woes
While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.
03/07 09:34 EST - seekingalpha.com
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.
03/07 08:00 EST - investors.com
Stock Market Drama Highlights Trump's Game Of Chicken With Economy
Uncertainty socked the U.S. stock market in February, short-circuiting an early-year rally and saddling fund investors with losses. The post Stock Market Drama Highlights Trump's Game Of Chicken With Economy appeared first on Investor's Business Daily.
Stock Market Drama Highlights Trump's Game Of Chicken With Economy
Uncertainty socked the U.S. stock market in February, short-circuiting an early-year rally and saddling fund investors with losses. The post Stock Market Drama Highlights Trump's Game Of Chicken With Economy appeared first on Investor's Business Daily.